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ORIGINAL ARTICLE 
Relationship between thyroid status and survival rates 
in patients presenting with acute coronary syndrome 
Ruth Caruana, Sandro Vella, Maryanne Caruana, Andrew Cassar, Josanne Vassallo
Thyroid dysfunction is a relatively common and treatable disease. 
The aims of the study included investigating the frequency of thyroid 
dysfunction in patients presenting with acute coronary syndrome 
(ACS) in our unit, following them up for 8 years and assessing the 
impact of thyroid dysfunction on their long-term outcome. 
Thyroid dysfunction is common among patients presenting with ACS 
in our unit. Forty one percent (n=36) of those included had abnormal 
thyroid function tests at presentation with ACS, with the most 
common condition being subclinical hypothyroidism. The mean age 
of all patients was 62.3 years and there was no significant age 
difference between males and females. There was no significant 
correlation between age and TSH and age and T4 levels. 
Forty two percent (n=37: 30 euthyroid, 7 thyroid dysfunction) died by 
the end of the observation period. A Kaplan-Meier curve was 
performed to check for any differences in survival across thyroid 
dysfunction categories. We report shorter survival times for patients 


















Ruth Caruana* MD MRCP MSc 
Clinical Nutrition 
Diabetes and Endocrine Unit, Mater 




Sandro Vella MD (Melit), MSc (Roeh), 
MD (Dund), FRCP (Edin), FRCP (Lond) 
Diabetes and Endocrine Unit, Mater 
Dei Hospital  
Msida, Malta 
 
Maryanne Caruana M.D.(Melit) 
Ph.D.(Melit) FRCP(Edin) FESC 
Department of Cardiology 




Department of Cardiology 
Dei Hospital  
Msida, Malta 
 
Josanne Vassallo MD PhD FRCP 
FACP FACE 
Department of Medicine 
Faculty of Medicine and Surgery 
University of Malta  







Malta Medical Journal     Volume 33 Issue 02 2021           
INTRODUCTION 
Thyroid dysfunction is relatively common, 
readily diagnosed and treatable. Most thyroid 
dysfunction is subclinical and is only diagnosed 
with the appropriate blood test. 
There are long term effects associated with 
thyroid dysfunction.  Overt hypothyroidism 
and hyperthyroidism are linked to adverse 
cardiovascular (CV) outcomes.1-2 Various 
studies have also shown that even in 
subclinical hypothyroidism and subclinical 
hyperthyroidism there is an increase in CV 
morbidity and mortality.3-7  
The reason for this association is that thyroid 
hormone receptors are found both in the heart 
and vasculature. Therefore, any changes in 
thyroid hormone levels will affect end organ 
function in these areas. The relationship of 
thyroid hormone with the CV system is 
complex and the effects are modulated in 
several different ways. Excess thyroid 
hormone effects on the heart include 
increased heart rate, contractility and overall 
risk of coronary heart disease. On the other 
hand thyroid hormone effects on vasculature 
include variation in smooth muscle tone and 
hence blood pressure.8-9 
Hyperthyroidism and therefore thyroid 
hormone excess, is associated with a 
hyperdynamic circulation, an increased cardiac 
output, subsequent development of systolic 
hypertension10 and an increased risk of 
coronary heart disease. Hypothyroidism and 
hence thyroid hormone deficiency, is 
associated with diastolic hypertension and 
impaired vascular function.11 Thyroid 
hormones increase endothelial production of 
nitric oxide and other changes which lead to 
changes in endothelial function due to smooth 
muscle relaxation.12 Consequently, in 
hypothyroidism this impaired endothelial 
function improves with replacement of thyroid 
hormone.13-14 In addition thyroid hormones 
have a direct effect on lipid metabolism with 
hyperthyroidism associated with decreased 
levels of cholesterol (TC)15 and hypothyroidism 
with higher low density lipoprotein cholesterol 
(LDL-C) levels.16 Once thyroid hormone levels 
normalized, lipid profiles return to normal in 
both hyper- and hypothyroidism. Thyroid 
hormones also modulate inflammatory and 
coagulation pathways. An overall increased 
hypercoagulability has been documented in 
hyperthyroidism,17 while conflicting results 
have been reported in hypothyroidism.18 
Overt and subclinical hyperthyroidism 
Hyperthyroidism and thyroid hormone excess 
cause increased cardiac output by increasing 
stroke volume and heart rate.19 However 
despite a high output state, hyperthyroid 
patients have reduced cardiopulmonary 
function during exercise due to decreased CV 
reserve20. Overt hyperthyroidism is associated 
with increased CV morbidity and mortality 
mainly due to an increased incidence of heart 
failure.21-22 Untreated hyperthyroidism may 
cause high output heart failure even in those 
with a previously healthy heart. 22 
Furthermore, hyperthyroidism is associated 
with increased risk of atrial ectopics and atrial 
fibrillation. The onset of atrial fibrillation is 
associated with increased CV morbidity and 
mortality.23 Subclinical hyperthyroidism was 
also shown to be associated with the 
development of atrial fibrillation.7 On the 
other hand, studies regarding the association 
of CV morbidity and mortality with subclinical 
hyperthyroidism provide conflicting data due 
to major differences in study design, methods 
and cut-offs used. Despite this, treatment of 
subclinical hyperthyroidism is advocated 
internationally especially if the patient has 
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other CV risk factors and a Thyroid Stimulating 
Hormone (TSH) suppressed to less than 
0.1mIU/L. In particular the European Thyroid 
Association guidelines recommend treatment 
in those with CV risk factors and a TSH 
<0.1mIU/L at any age. It is also suggested that 
if the patient is over 65 years and has 
underlying CV disease or history of fractures, 
treatment should be considered even if TSH is 
only mildly suppressed (0.1-0.39 mIU/L) in an 
attempt to decrease risk.24 
A well-known long term effect of both 
subclinical and clinical hyperthyroidism is 
increased bone turnover causing osteoporosis 
and increased risk of fractures.1,25 As described 
above, treatment is recommended to improve 
outcomes. 
Overt and subclinical hypothyroidism 
Overt hypothyroidism is associated with a 
reduction in cardiac output, decreased heart 
rate and increase in peripheral vascular 
resistance and diastolic dysfunction.26 There is 
an association of hypercholesterolemia, 
diastolic hypertension and reduced 
endothelial nitric oxide with overt 
hypothyroidism. Normalization of thyroid 
hormone levels causes reversal of these 
features.27 
Subclinical hypothyroidism is known to be 
associated with diastolic dysfunction due to 
impaired ventricular relaxation.28 Subclinical 
hypothyroidism was shown to be linked to an 
increased risk of congestive heart failure 
among adults with a TSH level of 7.0 mIU/L or 
greater.29 The Whickam Survey cohort showed 
that subclinical hypothyroidism is associated 
with dyslipidaemia namely higher TC levels, 
LDL-C levels, and triglycerides (TG).5,30 Higher 
TSH levels were associated with higher systolic 
and diastolic blood pressure.5,31-32 
Various studies have been published showing 
an association between CV outcomes and 
subclinical hypothyroidism. The EPIC- Norfolk 
study found a worse cardiovascular risk factor 
profile.33 However, this increased CV risk was 
not confirmed in all studies. Specifically 
subclinical hypothyroidism was not associated 
with increased risk for coronary heart 
disease,34-35 stroke,36 peripheral arterial 
disease,29 or CV-related or total mortality.29  
Current data on mortality is not conclusive. 
Subclinical hypothyroidism was shown to be 
associated with an increased risk of coronary 
heart disease and mortality in those with 
higher TSH levels,29 especially in those with a 
TSH concentration of 10 mIU/L or greater.34 
Subclinical hypothyroidism was also shown to 
be linked with an increased risk for all-cause 
mortality and CV death.37 On the other hand, 
another study has shown that subclinical 
hypothyroidism might be associated with a 
lower risk in all cause mortality.38 More recent 
studies showed no association with subclinical 
hypothyroidism and overall death in the 
elderly.39-40 However, treatment of subclinical 
hypothyroidism was shown not to improve 
either all cause mortality,41 or CV mortality.42 
Aim 
The aims of the study included investigating 
the frequency of thyroid dysfunction in 
patients presenting with acute coronary 
syndrome (ACS) to the Coronary Care Unit at St 
Luke's Hospital, Malta between 1st February 
2002 and 30th June 2003, follow-up of these 
patients at St. Luke's and Mater Dei hospitals 
until December 2010 and assessing the impact 
of thyroid dysfunction on patient outcomes. 
METHOD 
This was a prospective, case controlled study.  
Patients presenting with Acute Coronary 
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Syndrome (ACS) at St Luke's Hospital, Malta 
between February 2002 and June 2003 were 
included in the study.   
Exclusion criteria included ongoing treatment 
for thyroid dysfunction and ongoing treatment 
with beta-blockers and/or amiodarone. All 
patients who were admitted to CCU and did 
not fit in the exclusion criteria were included in 
this study. 
Data collected included anthropometric 
parameters at presentation; serum and plasma 
samples were taken within 24 hours of 
presentation for thyroid function tests, renal 
profiles, creatinine kinase, lipid profile, 
random blood glucose (RBG) and glycosylated 
haemoglobin. 
Additional data captured at presentation with 
ACS included diabetes subtype, current 
glucose lowering regime at presentation and 
cardiovascular risk factors, namely smoking, 
hypertension, dyslipidaemia, and family 
history. 
Subsequently, follow-up data was collected 
until December 2010. Cardiovascular 
complications were recorded together with 
readmission rates with coronary and other 
events, duration of hospital stay and mortality 
data. Information was collected both from 
hospital notes and death certificates. 
SPSS® 22.0 was used for data analysis. Mann-
Whitney U and Kruskal-Wallis tests were used 
to compare differences in continuous variables 
between thyroid categories. Chi Square test 
and Kruskal-Wallis tests were used to compare 
frequencies across thyroid categories. 
Spearman's correlation was used to correlate 
continuous variables. Kaplan Meier survival 
curve was used to compare survival rates 
across thyroid categories. Significance was 
defined by a two-tailed p value of < 0.05. 
Classification  
The classification of thyroid status was defined 
in Table 1 as follows: 
 
Table 1 Classification of Thyroid Status 
 
Thyroid status TSH and T4 concentration 
Overt hypothyroidism  TSH ≥ 10 mIU/L or TSH concentration > 4.00 mIU/L with 
a free T4 below 10.3 pmol/l 
Subclinical hypothyroidism  TSH concentration between 4 and 10 mIU/L with a 
normal free T4 (10.3-24.45pmol/l) 
Euthyroidism  TSH concentration 0.4 to 4.0 mIU/L 
Subclinical hyperthyroidism  TSH concentration > 0.1 and < 0.4 mIU/L with a normal 
free T4 (10.3-24.45 pmol/l) 
Overt thyrotoxicosis  TSH concentration < 0.10 mU/L  in the setting of a 
normal / elevated free T4 or a TSH value of 0.1- 0.4 in 
the setting of a high T4 or high T3 
Sick euthyroidism Can occur in any systemic illness and typically low FT3 
and/ or FT4 with low normal/normal TSH.  
26
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RESULTS 
There were a total of 201 patients admitted to 
the coronary care unit from February 2002 to 
June 2003 as shown in Figure 1. Out of these, 
88 patients admitted with ACS fitted the 
inclusion criteria. Another 6 were admitted 
with ACS but were already known to have 
thyroid dysfunction. 
 













Thirty-six patients (25 males, 11 females) had 
abnormal thyroid function tests at 
presentation with ACS. Thyroid dysfunction is 
common among patients presenting with ACS 
in Malta- 41% of our cohort were newly 
diagnosed with thyroid dysfunction on 
admission. Fifty nine percent of the cohort was 
euthyroid at presentation. The most common 
thyroid dysfunction was subclinical 
hypothyroidism which represented 17% of the 
cohort followed by subclinical hyperthyroidism 
in 12.5% of the cohort. 9% were overtly 
hypothyroid and 2.2% were overtly 
hyperthyroid. There were no patients who met 
the criteria for sick euthyroid syndrome given 
the available thyroid hormone parameters. 
The mean age of all patients was 62.3 years 
and there was no difference in baseline 
characteristics between males and females, as 
shown in table 2 below. 
There was no definitive correlation between 
age and TSH and age and T4 as shown in Figure 
2. Nonetheless, available data suggests a trend 
towards a weak correlation between TSH and 
age with a p value of 0.055.  
Normal thyroid and different abnormal thyroid 
cohorts were compared as shown in Table 3. 
TSH and fT4 levels were significantly different, 
as expected. There were no differences in age, 




156 pts included in 
study
68 lost to follow-up 88 remaining
52 (59%) euthyroid
36  (41%) Abnormal 
TFT
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Table 2 Baseline characteristics for all patients [Mean (SD) or frequency [%]* values] 
Baseline 
characteristic 






p value 1 
Age (years) 62.32 (13.44) 61.94 (12.70) 62.86 (14.60) 0.619 2 
TSH (mIU/L) 4.08 (8.74) 4.70 (10.65) 3.16 (4.75) 0.515 2 
FT4 (pmol/L) 15.56 (5.00) 15.33 (4.17) 16.13 (6.79) 0.909 2 
Random plasma 
glucose (mmol/L) 
9.30 (4.78) 8.76 (3.63) 10.17 (6.19) 0.608 2 
LDL-cholesterol 
(mmol/L) 
3.60 (1.25) 3.62 (1.08) 3.54 (1.53) 0.468 2 
HDL-cholesterol 
(mmol/L) 
1.32 (0.37) 1.28 (0.22) 1.39 (0.54) 0.221 2 
total cholesterol 
(mmol/L) 




20 (22.72) 12 (13.63) 8 (9.09) 0.905 3 
1 two-sided p value for the difference between male and female subgroups 
2 Mann-Whitney U test 
3 Chi Square test 
 














Malta Medical Journal     Volume 33 Issue 02 2021           








(n = 8) 
Subclinical    








p value 1 
Age (years) 64 68 67 60 42.5 0.175 
TSH (mIU/L) 1.5 13.05 5.48 0.30 0.05 0.000 
























































1 Independent Samples Kruskal-Wallis test 
 
Figure 3 shows thyroid status at presentation: 
52 patients were euthyroid, 8 were 
hypothyroid, 15 were subclinically 
hypothyroid, 2 were hyperthyroid and 11 were 
subclinically hyperthyroid. 
There was no difference in counts of thyroid 
categories across the genders although one 
can say there is a trend towards some 
difference with a p value of 0.051 (Chi squared). 
There was also no difference in age across 
patients with different thyroid categories 
(p=0.175- Independent Samples Kruskall Wallis 
test). 
Numbers were very small. In order to perform 
further survival statistics, patients were 
divided in 2 different groups as normal thyroid 
function and abnormal thyroid function on 
admission. There was no difference in survival 
status between the 2 groups- p=0.262 (Chi 
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Table 4 Deaths according to thyroid status 
Thyroid status Euthyroid Abnormal thyroid function p value1 
Survived 36 15  
0.262 Died 30 7 
 
 
Table 5 Mean survival times for patients presenting with an acute coronary syndrome, stratified 
 by thyroid status 
Thyroid status Mean survival time Lower 95% CI Upper 95% CI 
Euthyroid at presentation 1620.02 1318.51 1921.53 
Thyroid dysfunction at 
presentation 
2194.40 1941.77 2447.03 
 
Kaplan-Meier curve was performed to check 
for any differences in survival between 
patients with normal and abnormal thyroid 
function (Log rank test with a p value of 0.191). 
They were followed up for a maximum of 2636 
days (Table 5 and Figure 4). By the end of the 
observation period in 2010, 20 male and 17 
female patients had died. Causes of death 
stratified by thyroid status at presentation are 
summarised in table 6. 
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Figure 4 Kaplan-Meier curves comparing time to death for euthyroid patients and those with 

















Table 6 Causes of death across thyroid categories 
Cause of death Normal thyroid status Thyroid dysfunction 
Ischaemic/ congestive heart disease 5 2 
Cerebrovascular accident 0 2 
Other causes including pneumonia, 
sepsis 
3 3 






Malta Medical Journal     Volume 33 Issue 02 2021           
DISCUSSION 
As discussed previously, the most common 
thyroid dysfunction was subclinical 
hypothyroidism (15% of the cohort) followed 
by 12% who were subclinical hyperthyroid. Of 
note, no patients were noticed to have thyroid 
function tests showing the sick euthyroid 
pattern which would be expected in a hospital 
cohort. Low T3 levels post myocardial 
infarction due to sick euthyroid syndrome have 
been associated with molecular changes which 
cause depressed myocardial function and have 
been implicated in the potential development 
of heart failure post infarction.43 Our patients 
had their blood tests taken on admission, 
potentially prior to the occurrence of a sick 
euthyroid state although the lack of routine 
FT3 and rT3 estimations at the laboratory 
poses a limitation. However, T4 and TSH data 
did not show isolated hypothyroxinaemia. 
A significant number of patients (42.05%) died 
during follow-up. Analysis of biochemistry 
results of the whole cohort on admission, 
revealed that twenty one percent of the 
cohort had been diagnosed with diabetes and 
a significant number had additional co-
morbidities apart from coronary artery 
disease.  
We report shorter survival times for patients 
who are euthyroid at presentation with an 
ACS, a finding that was unexpected. Most 
studies in the field have shown the opposite.44-
45 An explanation for this result could be the 
small numbers involved. Another reason could 
be the methodology in having grouped all 
thyroid dysfunction (hypothyroid and 
hyperthyroid) patients together in one cohort. 
In our cohort the euthyroid group had more 
diabetics than the dysthyroid group. This may 
have masked any opposing effects of these 
conditions. 
In our study, there were 27 euthyroid males 
and 25 euthyroid females and a total of 25 
male patients with thyroid dysfunction and 11 
female patients with thyroid dysfunction. This 
is unusual as thyroid dysfunction is generally 
more common in females than males. In 
addition, women with IHD have higher rates of 
death compared to men after myocardial 
infarction46. It is possible that females in this 
cohort had more comorbidities eg higher RBG 
in women. Therefore, it could be that our 
results show a reverse mortality trend due to 
the gender bias, i.e. more males and hence less 
mortality.  
A possible explanation may be that patients 
who have thyroid dysfunction are inevitably 
followed up because of the thyroid 
dysfunction itself and hence other issues may 
be picked up earlier and treated accordingly 
improving their survival compared to 
euthyroid patients. 
Another explanation for our results could be 
that having thyroid dysfunction itself might 
have been the reason for the patients’ ACS and 
hence this was easily treatable, thus 
decreasing mortality. On the other hand, 
patients who were euthyroid and had ACS, 
probably had non-reversible or difficult to 
treat causes for their IHD like hereditary 
causes, smoking or significant co-morbidities. 
Limiting Factors 
The whole cohort was a convenience sample 
and therefore it may not represent a normal 
distribution. As discussed already we had very 
small numbers and in addition many more male 
patients than female patients which may have 
skewed the results. Follow up data collection 
was retrospective and 68 case notes were 
unavailable (Figure 1). Hence these patients 
were lost to follow-up and not included in the 
32
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study. This amounted to almost a third of the 
cohort. 
Diabetes has a huge impact in the outcome of 
ACS treatment. Twenty percent of our cohort 
had diabetes at presentation and this may 
have influenced their outcomes (n=20 of which 
13 where euthyroid and 7 were dysthyroid). 
Management of patients of ACS varies starting 
from PCI to conservative management. We did 
not collect any data about the management of 
the ACS since this was beyond the scope of our 
study. However, the outcomes of these 
patients definitely may have been influenced 
by the type of treatment for their ACS.  
Another problem was the methodology used 
for the Kaplan Meier analysis in grouping 
normal thyroid function group and abnormal 
thyroid function group. In grouping the 
different thyroid categories the analysis may 
have been skewed. Given the findings 
reported here, there is clearly a need for a 
larger prospective, case controlled study with 
prospective data collection and analysis. 
CONCLUSIONS 
Thyroid dysfunction is common among 
patients presenting with ACS in Malta, the 
most common being subclinical 
hypothyroidism. We report and discuss the 
observed shorter survival times for patients 
who are euthyroid at presentation with an 
acute coronary syndrome. 
SUMMARY BOX 
What is already known about this subject: 
• Current data on mortality is not 
conclusive.  
• Overt hypothyroidism and 
hyperthyroidism are linked to adverse CV 
outcomes.  
• Various studies have also shown that 
even in subclinical hypothyroidism and 
subclinical hyperthyroidism there is an 
increase in CV morbidity and mortality. 
What are the new findings: 
• Thyroid dysfunction is common among 
patients presenting with ACS in Malta. 
Diabetes was also very common in the 
above cohort which may be a 
confounding factor.  
• The most common dysfunction being 
subclinical hypothyroidism.  
• We report shorter survival times for 
patients who are euthyroid at 
presentation with an acute coronary 
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